Fact CheckerSign in

NCT05179824Active, not recruiting

Tempus Priority Study: A Pan-tumor Observational Study

Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling

Source: ClinicalTrials.gov · Last updated 6 May 2025

Brief summary (registry, in English)

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
1000 (estimated)
First submitted
16 Dec 2021
Start date
19 Oct 2020
Primary completion date
19 Oct 2026
Lead sponsor
Tempus AI
NCT number
NCT05179824

What you commit to

  • Study type: Observational
  • Planned participants: 1000
  • From 19 Oct 2020 to the primary completion date, 19 Oct 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Individuals without the capacity to consent.
  • Prisoners at the time of enrollment.

Who the study is looking for

  • Solid or hematologic malignancy.
  • Willing and able to provide informed consent where required.
  • Has received or will receive genomic profiling.

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
UT Southwestern
Coordinator of this site? Confirm its status
DallasUnited StatesUnknown status
Baylor College of Medicine
Coordinator of this site? Confirm its status
HoustonUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.